Last reviewed · How we verify
Adductor canal regional block
At a glance
| Generic name | Adductor canal regional block |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- From Battlefield to Recovery: Continuous Regional Anaesthesia for War-Related Lower Limb Trauma
- Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (PHASE4)
- Postoperative Analgesic Benefit of iPACK Block in the Anterior Cruciate Ligament Reconstruction Surgery (NA)
- Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (PHASE1, PHASE2)
- Zynrelef Versus Adductor Canal Block (PHASE4)
- Evaluation of the Effectiveness of iPACK and Adductor Canal Blocks on Patients Undergoing Arthroscopic Knee Surgery (NA)
- Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA (NA)
- ACB With S-ESPB Versus ACB With iPACK for Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adductor canal regional block CI brief — competitive landscape report
- Adductor canal regional block updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI